TherapeuticsMD (TXMD) Competitors

$2.12 0.00 (0.00%)

As of 05/22/2026 04:00 PM Eastern

TXMD vs. UPXI, ANIX, BMEA, ICCC, and CLNN

Should you buy TherapeuticsMD stock or one of its competitors? MarketBeat compares TherapeuticsMD with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TherapeuticsMD include Upexi (UPXI), Anixa Biosciences (ANIX), Biomea Fusion (BMEA), ImmuCell (ICCC), and Clene (CLNN). These companies are all part of the "pharmaceutical products" industry.

How does TherapeuticsMD compare to Upexi?

TherapeuticsMD (NASDAQ:TXMD) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

In the previous week, Upexi had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for Upexi and 0 mentions for TherapeuticsMD. Upexi's average media sentiment score of 0.59 beat TherapeuticsMD's score of 0.00 indicating that Upexi is being referred to more favorably in the news media.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Upexi	Positive

TherapeuticsMD has a net margin of 5.34% compared to Upexi's net margin of -874.00%. TherapeuticsMD's return on equity of 0.32% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Upexi	-874.00%	-66.70%	-19.56%

Upexi has a consensus price target of $8.33, suggesting a potential upside of 521.89%. Given Upexi's stronger consensus rating and higher probable upside, analysts plainly believe Upexi is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by insiders. Comparatively, 9.0% of Upexi shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

TherapeuticsMD has higher earnings, but lower revenue than Upexi. Upexi is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.12	-$570K	$0.06	35.33
Upexi	$15.81M	5.95	-$13.68M	-$0.62	N/A

TherapeuticsMD has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, Upexi has a beta of -0.32, indicating that its stock price is 132% less volatile than the broader market.

Summary

TherapeuticsMD beats Upexi on 9 of the 17 factors compared between the two stocks.

How does TherapeuticsMD compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

In the previous week, Anixa Biosciences had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for Anixa Biosciences and 0 mentions for TherapeuticsMD. Anixa Biosciences' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Anixa Biosciences	Neutral
TherapeuticsMD	Neutral

Anixa Biosciences has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to Anixa Biosciences' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-70.95%	-62.53%
TherapeuticsMD	5.34%	0.32%	0.23%

TherapeuticsMD has higher revenue and earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	445.47	-$10.93M	-$0.33	N/A
TherapeuticsMD	$3.02M	8.12	-$570K	$0.06	35.33

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Anixa Biosciences presently has a consensus target price of $8.50, suggesting a potential upside of 204.66%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Anixa Biosciences is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats Anixa Biosciences on 8 of the 15 factors compared between the two stocks.

How does TherapeuticsMD compare to Biomea Fusion?

Biomea Fusion (NASDAQ:BMEA) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

TherapeuticsMD has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A
TherapeuticsMD	$3.02M	8.12	-$570K	$0.06	35.33

Biomea Fusion currently has a consensus target price of $8.29, indicating a potential upside of 483.50%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Biomea Fusion had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 2 mentions for Biomea Fusion and 0 mentions for TherapeuticsMD. Biomea Fusion's average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Biomea Fusion	Neutral
TherapeuticsMD	Neutral

Biomea Fusion has a beta of -0.32, suggesting that its stock price is 132% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

TherapeuticsMD has a net margin of 5.34% compared to Biomea Fusion's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-265.37%	-103.96%
TherapeuticsMD	5.34%	0.32%	0.23%

96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 18.4% of Biomea Fusion shares are held by insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

TherapeuticsMD beats Biomea Fusion on 8 of the 15 factors compared between the two stocks.

How does TherapeuticsMD compare to ImmuCell?

ImmuCell (NASDAQ:ICCC) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ImmuCell had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for ImmuCell and 0 mentions for TherapeuticsMD. ImmuCell's average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
ImmuCell	Neutral
TherapeuticsMD	Neutral

TherapeuticsMD has lower revenue, but higher earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$27.64M	3.31	-$1.04M	-$0.06	N/A
TherapeuticsMD	$3.02M	8.12	-$570K	$0.06	35.33

TherapeuticsMD has a net margin of 5.34% compared to ImmuCell's net margin of -1.82%. TherapeuticsMD's return on equity of 0.32% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
TherapeuticsMD	5.34%	0.32%	0.23%

ImmuCell has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 5.7% of ImmuCell shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

TherapeuticsMD beats ImmuCell on 9 of the 12 factors compared between the two stocks.

How does TherapeuticsMD compare to Clene?

TherapeuticsMD (NASDAQ:TXMD) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

TherapeuticsMD has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	8.12	-$570K	$0.06	35.33
Clene	$200K	428.13	-$26.17M	-$3.20	N/A

TherapeuticsMD has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Clene has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

In the previous week, Clene had 6 more articles in the media than TherapeuticsMD. MarketBeat recorded 6 mentions for Clene and 0 mentions for TherapeuticsMD. Clene's average media sentiment score of 0.67 beat TherapeuticsMD's score of 0.00 indicating that Clene is being referred to more favorably in the news media.

Company	Overall Sentiment
TherapeuticsMD	Neutral
Clene	Positive

Clene has a consensus target price of $33.25, indicating a potential upside of 396.27%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

TherapeuticsMD has a net margin of 5.34% compared to Clene's net margin of -25,009.70%. TherapeuticsMD's return on equity of 0.32% beat Clene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Clene	-25,009.70%	N/A	-137.98%

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

TherapeuticsMD and Clene tied by winning 8 of the 16 factors compared between the two stocks.

Get TherapeuticsMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXMD vs. The Competition

Export

Metric	TherapeuticsMD	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.54M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	35.33	17.79	21.00	25.66
Price / Sales	8.12	336.21	558.19	86.31
Price / Cash	45.44	57.74	43.49	56.67
Price / Book	0.91	5.86	10.40	7.14
Net Income	-$570K	$74.99M	$3.57B	$335.98M
7 Day Performance	3.92%	3.11%	6.40%	4.11%
1 Month Performance	-3.20%	-3.05%	3.55%	2.52%
1 Year Performance	46.21%	34.38%	34.13%	35.04%

TherapeuticsMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXMD TherapeuticsMD	0.6037 of 5 stars	$2.12 flat	N/A	+46.2%	$24.54M	$3.02M	35.33	420
UPXI Upexi	1.7989 of 5 stars	$1.29 -2.3%	$8.33 +546.0%	-87.5%	$92.75M	$15.81M	N/A	130	Gap Up
ANIX Anixa Biosciences	1.8959 of 5 stars	$2.67 -3.3%	$8.50 +218.4%	+11.6%	$92.54M	$210K	N/A	5	Upcoming Earnings
BMEA Biomea Fusion	2.0124 of 5 stars	$1.22 -2.4%	$8.29 +579.2%	-4.1%	$90.37M	N/A	N/A	50
ICCC ImmuCell	0.4945 of 5 stars	$10.20 +2.9%	N/A	+55.2%	$89.65M	$29.93M	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXMD) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TherapeuticsMD (TXMD) Competitors

TXMD vs. UPXI, ANIX, BMEA, ICCC, and CLNN

How does TherapeuticsMD compare to Upexi?

Summary

How does TherapeuticsMD compare to Anixa Biosciences?

Summary

How does TherapeuticsMD compare to Biomea Fusion?

Summary

How does TherapeuticsMD compare to ImmuCell?

Summary

How does TherapeuticsMD compare to Clene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TherapeuticsMD (TXMD) Competitors

TXMD vs. UPXI, ANIX, BMEA, ICCC, and CLNN

How does TherapeuticsMD compare to Upexi?

Does the media favor TXMD or UPXI?

Is TXMD or UPXI more profitable?

Do analysts rate TXMD or UPXI?

Do institutionals and insiders believe in TXMD or UPXI?

Which has higher earnings and valuation, TXMD or UPXI?

Which has more risk & volatility, TXMD or UPXI?

Summary

How does TherapeuticsMD compare to Anixa Biosciences?

Does the media favor ANIX or TXMD?

Which has more risk & volatility, ANIX or TXMD?

Is ANIX or TXMD more profitable?

Which has preferable valuation & earnings, ANIX or TXMD?

Do institutionals & insiders hold more shares of ANIX or TXMD?

Do analysts recommend ANIX or TXMD?

Summary

How does TherapeuticsMD compare to Biomea Fusion?

Which has higher valuation & earnings, BMEA or TXMD?

Do analysts rate BMEA or TXMD?

Does the media prefer BMEA or TXMD?

Which has more volatility and risk, BMEA or TXMD?

Is BMEA or TXMD more profitable?

Do insiders & institutionals have more ownership in BMEA or TXMD?

Summary

How does TherapeuticsMD compare to ImmuCell?

Do analysts rate ICCC or TXMD?

Does the media favor ICCC or TXMD?

Which has stronger earnings and valuation, ICCC or TXMD?

Is ICCC or TXMD more profitable?

Which has more risk & volatility, ICCC or TXMD?

Do institutionals and insiders have more ownership in ICCC or TXMD?

Summary

How does TherapeuticsMD compare to Clene?

Which has higher earnings and valuation, TXMD or CLNN?

Which has more volatility and risk, TXMD or CLNN?

Does the media favor TXMD or CLNN?

Do analysts prefer TXMD or CLNN?

Is TXMD or CLNN more profitable?

Do institutionals & insiders have more ownership in TXMD or CLNN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXMD vs. The Competition

TherapeuticsMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools